BioLife Solutions, Inc.

Valuation Analysis

About the Company

BioLife Solutions, Inc. en bref

BioLife Solutions, Inc. (BLFS) is currently trading at 22,72 € with a market capitalization of 1,1 Md €. The 52-week range spans from 15,59 € to 25,85 €; the current price is 12.1% below the yearly high. Year-over-year revenue growth stands at +24.7%.

💰 Dividende

BioLife Solutions, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

10 analystes évaluent BioLife Solutions, Inc. (BLFS) au consensus : Achat Fort. L'objectif de cours moyen est de 28,19 €, soit un potentiel de +24.04% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 26,18 € à 29,67 €.

BioLife Solutions, Inc. : la thèse d'investissement en détail

BioLife Solutions, Inc. (BLFS) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 24.7% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 63.76%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 24.04% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 1.97, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 12.74% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

At a PEG of 15.09, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 282.75x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The analyst consensus price target implies 24.04% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (12.74%).

Trading Data

Related Stocks in the Same Sector

Where can I buy BioLife Solutions, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.